Early and multiple origins of metastatic lineages within primary tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 8, 2016, Pages 2140-2145

  Zhao, Zi Ming ^a   Zhao, Bixiao ^b   Bai, Yalai ^b   Iamarino, Atila ^a   Gaffney, Stephen G ^a   Schlessinger, Joseph ^b   Lifton, Richard P ^b   Rimm, David L ^b   Townsend, Jeffrey P ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN; PROTEIN ALK; PROTEIN KMT2C; PROTEIN KMT2D; PROTEIN P53; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CELL LINEAGE; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; EXOME; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG METASTASIS; MAXIMUM LIKELIHOOD METHOD; METASTASIS; MOLECULAR EVOLUTION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PARAPHYLY; PHYLOGENETIC TREE; PHYLOGENY; PRIMARY TUMOR; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SILENT MUTATION; SOMATIC MUTATION; TELOMERE HOMEOSTASIS; BIOLOGICAL MODEL; CELL TRANSFORMATION; FEMALE; GENETIC VARIATION; GENETICS; MALE; MUTATION; NEOPLASM; ONCOGENE; PATHOLOGY; STATISTICAL MODEL; TIME FACTOR;

CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; EVOLUTION, MOLECULAR; FEMALE; GENETIC VARIATION; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MODELS, GENETIC; MUTATION; NEOPLASM METASTASIS; NEOPLASMS; ONCOGENES; PHYLOGENY; TIME FACTORS;

EID: 84959418842     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1525677113     Document Type: Article

References (52)

1. Gerlinger M, et al. (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46(3):225-233.
2. Weinberg RA (1991) Tumor suppressor genes. Science 254(5035):1138-1146.
3. Harbst K, et al. (2014) Molecular and genetic diversity in the metastatic process of melanoma. J Pathol 233(1):39-50.
4. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274-284.
5. Lawrence MS, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499(7457):214-218.
6. Lawrence MS, et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505(7484):495-501.
7. Naxerova K, Jain RK (2015) Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol 12(5):258-272.
8. Miller CA, et al. (2014) SciClone: Inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLOS Comput Biol 10(8):e1003665.
9. Swofford DL (2003) PAUP, Phylogenetic Analysis Using Parsimony ( and Other Methods), Version 4.
10. Zwickl DJ (2006) Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. PhD thesis (The University of Texas, Austin).
11. Ronquist F, et al. (2012) MrBayes 3.2: Efficient Bayesian phylogenetic inference and model choice across a large model space. Syst Biol 61(3):539-542.
12. Rew DA, Wilson GD (2000) Cell production rates in human tissues and tumours and their significance. Part II: Clinical data. Eur J Surg Oncol 26(4):405-417.
13. Hynes RO (2003) Metastatic potential: Generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113(7):821-823.
14. Burrell RA, McGranahan N, Bartek J, Swanton C (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467):338-345.
15. Hong WS, Shpak M, Townsend JP (2015) Inferring the origin of metastases from cancer phylogenies. Cancer Res 75(19):4021-4025.
16. Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9(4):302-312.
17. Baum M, Demicheli R, Hrushesky W, Retsky M (2005) Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases? Eur J Cancer 41(4):508-515.
18. Gray JW (2003) Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 4(1):4-6.
19. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
20. Wang S, et al. (2014) SAR405838: An optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res 74(20):5855-5865.
21. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477):548-551.
22. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR (2012) Regulating the regulator: Posttranslational modification of RAS. Nat Rev Mol Cell Biol 13(1):39-51.
23. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11-22.
24. Harfe BD, Jinks-Robertson S (2000) DNA mismatch repair and genetic instability. Annu Rev Genet 34:359-399.
25. Vasan N, et al. (2014) A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: Implications for clinical practice. Oncologist 19(5):453-458.
26. Goh G, et al. (2014) Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 46(6):613-617.
27. ChoiM, et al. (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331(6018):768-772.
28. Li H, et al.; 1000 Genome Project Data Processing Subgroup (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16):2078-2079.
29. Yang Z (2007) PAML 4: Phylogenetic analysis by maximum likelihood. Mol Biol Evol 24(8):1586-1591.
30. Tomasetti C, Vogelstein B, Parmigiani G (2013) Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci USA 110(6):1999-2004.
31. Palles C, et al.; CORGI Consortium; WGS500 Consortium (2013) Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45(2):136-144.
32. Lynch M (2010) Rate, molecular spectrum, and consequences of human mutation. Proc Natl Acad Sci USA 107(3):961-968.
33. Tokuda Y, et al. (1990) Fundamental study on the mechanism of DNA degradation in tissues fixed in formaldehyde. J Clin Pathol 43(9):748-751.
34. Yu YP, Michalopoulos A, Ding Y, Tseng G, Luo J-H (2014) High fidelity copy number analysis of formalin-fixed and paraffin-embedded tissues using Affymetrix Cytoscan HD chip. PLoS One 9(4):e92820.
35. Townsend JP, Su Z, Tekle YI (2012) Phylogenetic signal and noise: Predicting the power of a data set to resolve phylogeny. Syst Biol 61(5):835-849.
36. Sukumaran J, Holder M (2008) SumTrees, Summarization of Split Support on Phylogenetic Trees (part of the DendroPy Phylogenetic Computation Library), Version 2(3).
37. Yang Z (2006) Computational Molecular Evolution (Oxford Univ Press, Oxford).
38. Rambaut A, Drummond A, Suchard M (2013) Tracer, Version 1. 6
39. Erba E, et al. (1994) Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. Ann Oncol 5(7):627-634.
40. Choi J-H, Wong AST, Huang H-F, Leung PCK (2007) Gonadotropins and ovarian cancer. Endocr Rev 28(4):440-461.
41. Rew DA, Thomas DJ, Coptcoat M, Wilson GD (1991) Measurement of in vivo urological tumour cell kinetics using multiparameter flow cytometry: Preliminary study. Br J Urol 68(1):44-48.
42. Oda T, et al. (2001) Growth rates of primary andmetastatic lesions of renal cell carcinoma. Int J Urol 8(9):473-477.
43. Zhang J, Kang SK, Wang L, Touijer A, Hricak H (2009) Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology 250(1):137-144.
44. Schofield MJ, Hsieh P (2003) DNA mismatch repair: Molecular mechanisms and biological function. Annu Rev Microbiol 57:579-608.
45. Kariola R, et al. (2004) MSH6 missense mutations are often associated with no or low cancer susceptibility. Br J Cancer 91(7):1287-1292.
46. Edelmann W, et al. (1997) Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91(4):467-477.
47. Rowland MM, Schonhoft JD, McKibbin PL, David SS, Stivers JT (2014) Microscopic mechanism of DNA damage searching by hOGG1. Nucleic Acids Res 42(14):9295-9303.
48. Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005. Mutat Res 577(1-2):275-283.
49. Stanton PD, Cooke TG, Forster G, Smith D, Going JJ (1996) Cell kinetics in vivo of human breast cancer. Br J Surg 83(1):98-102.
50. Nik-Zainal S, et al.; Breast Cancer Working Group of the International Cancer Genome Consortium (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979-993.
51. Ostrow SL, Barshir R, DeGregori J, Yeger-Lotem E, Hershberg R (2014) Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet 10(3):e1004239.
52. Sottoriva A, et al. (2015) A Big Bang model of human colorectal tumor growth. Nat Genet 47(3):209-216.